Abstract
PHNO, a new D-2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose-ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.
MeSH terms
-
Administration, Oral
-
Adult
-
Aged
-
Carbidopa / administration & dosage
-
Carbidopa / therapeutic use
-
Dopamine Agents / administration & dosage
-
Dopamine Agents / adverse effects
-
Dopamine Agents / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
Humans
-
Levodopa / administration & dosage
-
Levodopa / therapeutic use
-
Male
-
Middle Aged
-
Oxazines / administration & dosage
-
Oxazines / adverse effects
-
Oxazines / therapeutic use*
-
Parkinson Disease, Secondary / chemically induced
-
Parkinson Disease, Secondary / drug therapy*
-
Parkinson Disease, Secondary / pathology
-
Reaction Time
Substances
-
Dopamine Agents
-
Drug Combinations
-
Oxazines
-
carbidopa, levodopa drug combination
-
naxagolide
-
Levodopa
-
Carbidopa